Vivace Therapeutics
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1510 Fashion Island Blvd Ste 310, San Ma...Website
www.vivacetherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
1
1
About Vivace Therapeutics
Vivace Therapeutics is an oncology-focused small molecule drug discovery and development company based in the San Francisco Bay Area, dedicated to creating first-in-class cancer therapeutics. They leverage innovative science and novel pathways, particularly targeting the Hippo-YAP signaling pathway, to develop treatments that could address various forms of cancer. The company's experienced management and world-class scientists work collaboratively to advance promising drug candidates, aiming to deliver effective therapies to patients in need. Their strategic business approach seeks to generate exceptional value for shareholders while fighting against cancer.Explore more
Vivace Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vivace Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Vivace Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Vivace Therapeutics has new funding data
Product Launch: Get notified when Vivace Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Check out if Vivace Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Vivace Therapeutics
Vivace Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Vivace Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Vivace Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Vivace Therapeutics
Find 2 more new buyers
Compare Similar Companies to Vivace Therapeutics
Compare insights from companies similar to Vivace Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Vivace Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Vivace Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Vivace Therapeutics.
Vivace Therapeutics financials insights
Gather financial insights about Vivace Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$15M
2017
Series B
$25M
2020
Series C
$30M
2025
Series D
$35M
Vivace Therapeutics Tech Stack
A closer look at the technologies used by Vivace Therapeutics
See more technologies
Vivace Therapeutics News & Media
New Clinical Data for Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy to be Presented in Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2025
VT3989, a First-in-Class TEAD Autopalmitoylation Inhibitor, is the First Therapy Targeting the Hippo Pathway to Demonstrate Compelling Clinical Activity in Cancer New Data Adds to Clinical Findings Supporting VT3989's Potential as a Best-in-Class Therapeutic, with Initial Focus on the...Vivace Therapeutics' VT3989 Granted Fast Track Designation by the U.S. Food and Drug Administration for the Treatment of Mesothelioma
SAN MATEO, Calif., Oct. 8, 2025 /PRNewswire/ -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...Funding Roundup: Recent Financing Rounds Completed for Pain, Cancer, and ...
Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective financing rounds.Vivace Therapeutics Raises $35 Million in Series D Financing to Support Clinical Development of First-in-Class Cancer Drug Targeting the Hippo Pathway
Financing Led by RA Capital Management with Participation from Other Existing Investors Canaan Partners and Cenova Capital VT3989 is the Only TEAD Autopalmitoylation Inhibitor for which Compelling Clinical Efficacy Data Have Been Reported, Highlights Best-in-Class Profile Funding will...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vivace Therapeutics
Sign Up For FreeTo access detailed company insights
Vivace Therapeutics is an oncology-focused small molecule drug discovery and development company based in the San Francisco Bay Area, dedicated to creating first-in-class cancer therapeutics. They leverage innovative science and novel pathways, particularly targeting the Hippo-YAP signaling pathway, to develop treatments that could address various... Read More
